About US
Contact us
-
Bayer envisions bigger Eylea market with new EU useBayerhas taken another step toward fulfilling blockbuster ambitions for its eye drugEylea. The German drugmaker asked European regulators to approve the vision-loss treatment for patients with diabeti2013/11/8
-
Januvia's Q3 Performanc​e Proves Importance of Business Strategy for Type 2 Diabetes DrugsFollowing what was once the rising success of Merck’s first-to-market DPP-4 inhibitor, Januvia, which achieved significant sales of $4 billion in 2012, the unexpectedly poor performance of the type 22013/11/7
-
Novartis plots sales cuts in U.K. amid R&D restructuringNovartis ($NVS) has brought its job-cutting sword to the U.K., with plans to shutter an R&D site in Horsham. Up to 371 jobs are expected to disappear there. But that's not all. The Swiss drugmaker2013/11/7
-
Capsugel Completes Acquisition of Bend ResearchMORRISTOWN, N.J. – Capsugel announced today that it has completed its acquisition of Bend Research Inc., a recognized industry leader in bioavailability enhancement. Bend Research is now part of Capsu2013/11/6
-
Merck Millipore Launches Lockable ICRplus Settle Plates for Safe and Efficient Viable Air Monitoring and Personnel MonitoringMerck Millipore, the Life Science division of Merck, has launched lockable ICRplus Settle Plates for viable air monitoring and personnel monitoring in clean rooms and isolators. The new plates are2013/11/6
-
Aesica Introduces Aseptic Micro Dosing Capabilities at Nottingham SiteAesica,a global contract development and manufacturing organisation (CDMO), has introduced 3P’s Fill2Weight dispensing system — suitable for all powder formulations including spray dried and lyophilis2013/11/5
-
Stem Cell Therapeutics obtains FDA orphan drug status for leukaemia drugCanadian biopharmaceutical development firm Stem Cell Therapeutics (SCT) has received an orphan drug designation from the US Food and Drug Administration (FDA) for the use of tigecycline to treat acut2013/11/5
-
FDA helps generic drugmakers get copies of Glaxo's Advair to marketGlaxoSmithKline's asthma drug Advair is hard to copy. The British pharma ($GSK) has said it time and again, and recently, generics giant Teva backed up that claim, saying producing a generic would be2013/11/4
-
Roche's Rituxan successor first up in market scramble for first-line treatment of CLLA number of drugmakers have been looking to get drugs across the finish line for approval of first-line use in the treatment of chronic lymphocytic leukemia (CLL), and Roche's ($RHHBY) Genentech and B2013/11/4
-
DSM and Opthea Sign Agreement to Manufacture Opthea’s Lead Product for Eye DiseaseDSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has signed an agreement with Opthea Pty Ltd of Melbourne, Australia. The contract covers process developmen2013/11/1